OCLG
Seite 5 von 6 Neuester Beitrag: 25.04.21 03:55 | ||||
| Eröffnet am: | 01.02.11 04:15 | von: buran | Anzahl Beiträge: | 145 |
| Neuester Beitrag: | 25.04.21 03:55 | von: Birgitpevaa | Leser gesamt: | 19.463 |
| Forum: | Hot-Stocks | Leser heute: | 5 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | 4 | | 6 > | ||||
http://ih.advfn.com/p.php?pid=nmona&article=61903119
Oncologix Posts Solid Revenue Growth and Continued Financial Improvements
ALEXANDRIA, LA--(Marketwired - Apr 21, 2014) - Oncologix Tech Inc. (OTCQB: OCLG), a medical device and healthcare service holding company announced today its Second Quarter and YTD Fiscal 2014 results.
Wayne Erwin, CEO of Oncologix, stated, "Our progress and hard work are evidenced by the company's fiscal year 2014 second quarter and year-to-date financial results. Revenues during the periods were $983,758 and $1,708,391, respectively. When compared to the company posting zero revenues for the comparable periods in fiscal 2013, we think it's an important milestone that revenues are continuing to build for the year. Also, during the six months ending February 28, 2014, the company repaid over $400,000 of debt. It's evident from these results that we are executing our two-prong strategy that focuses on acquisitions and debt reduction; both of which have significantly enhanced Oncologix's market value. Other key indicators of our six month February 28, 2014 financials are:
Mid-Year 2014 Key Company Activities:
Revenues for the three and six months were $983,758 and $1,708,391, respectively.
Acquired Amian Health Services -- adding $1,000,000 in annual revenues
Executed a $4,000,000 line of credit facility with $300,000,000 TCA Global Fund to augment our acquisition strategy
Repaid over $400,000 in debt
Reduced annualized rents by $50,000
Reduced non-essential FTE employees by $148,000 per year
Began new product development for Dotolo Research Toxygen-II hardware system
Relocated Dotolo Research Corporation manufacturing facilities to Tempe, AZ
Increased our authorized stock to 750mm shares
Erwin also noted, "To continue our mid-year success, we'll execute further our acquisition strategy. We are currently in due diligence with two additional healthcare service companies with revenues exceeding $5,000,000 and generating $800,000 in annualized earnings. Overall, our company objective is to reach $10,000,000 in annualized revenues by fiscal year end. We believe that our stock price is currently undervalued and the debt reduction effort and strategic acquisitions will increase our stock values in the near term."
Oncologix operates and manufactures Class II medical device products and delivers Personal Healthcare Services nationally. For its clients, Oncologix provides FDA approved medical devices and State licensed healthcare services. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company's corporate mission is to be the best small cap medical device and healthcare services holding company in North America.
Forward Looking Statement
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Company's expectations, among other things, are dependent upon economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, its ability to operate its subsidiary companies effectively, need for and availability of more capital as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's filings with the Securities and Exchange Commission.
CONTACT INFORMATION
Wayne Erwin
Chairman and CEO
Email Contact
(318) 451-9543
INVESTOR RELATIONS
Jack Eversull
President
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
Email Contact
Neue Firmen zukaufen und gleichzeitig ihre Schulden Stück für Stück abbauen.
Irgendwann wird sich auch hier eine faire Bewertung einstellen :-)
Optionen
| Boardmail an "buran" |
Wertpapier: Oncologix Tech Inc |
http://www.otcmarkets.com/news/otc-market-headline?id=16293029
Jul 16, 2014 (ACCESSWIRE via COMTEX) -- ALEXANDRIA, LA / ACCESSWIRE / July 15, 2014 / Oncologix Tech Inc. (OTC Pink: OCLG), a diversified medical holding company with division in medical devices and healthcare services released its Third Quarter and YTD Fiscal 2014 results.
Wayne Erwin, CEO of Oncologix, stated, "We are pleased to announce our third quarter and year to date fiscal 2014 financials. Revenues during the periods were $988,385 and $2,696,776, respectively. When compared to the company posting minimal revenues for the comparable periods in FY 2013, we think it's an important milestone to recognize that revenues are continuing to build for the year. Also, during the nine months ending May 31, 2014, the company repaid over $700,000 of debt. It's evident from these results that we are executing our two-prong strategy that focuses on strategic acquisitions and debt reduction both of which have significantly enhanced Oncologix's market value.
2014 Key Company Activities through May 2014:
- Revenues for the three and nine months were $988,385 and $2,696,776, respectively.
- Rent Reductions: Reduced annualized rents by $50,000
- Acquired Amian Health Services - $1.1million in annual revenues
- Reduction in non-essential FTE employees- Realize annual savings over $75,000
- Began new product development for Dotolo Research Corporation Toxygen-II hardware system and new disposable products with E& R Engineering, Schmitt Engineering, and Atom Design
- Relocated Dotolo Research Corporation manufacturing facilities to E&R engineering manufacturing in Tempe, AZ
- Executed a $4.0 million line of credit facility with TCA Global Fund
- Increased our authorized shares to 750 million shares
- Repaid over $700,000 in debt during the nine months ending February 28, 2014
Erwin also noted, "To continue with current-year success, we'll execute further upon our acquisition strategy. We are currently in the final due diligence stage with three (3) additional companies, a medical device company with revenues exceeding $1,400,000 generating $600,000 in annualized earnings, and two medical product/equipment companies with combined revenues exceeding $18,000,000 and generating $2,100,000 in annualized earnings. Overall, our YE 2014 company objective is to reach $20,000,000 in annualized revenues by calendar end. We believe that our stock price is severely undervalued and by continuing on our debt reduction efforts and executing on strategic acquisitions, we will certainly expect an increase in our stock values in the near term."
NEWS: Oncologix Post Solid Revenue Growth and Continued Financial Improvements
http://www.otcmarkets.com/news/otc-market-headline?id=16293029
Jul 16, 2014 (ACCESSWIRE via COMTEX) -- ALEXANDRIA, LA / ACCESSWIRE / July 15, 2014 / Oncologix Tech Inc. (OTC Pink: OCLG), a diversified medical holding company with division in medical devices and healthcare services released its Third Quarter and YTD Fiscal 2014 results.
Wayne Erwin, CEO of Oncologix, stated, "We are pleased to announce our third quarter and year to date fiscal 2014 financials. Revenues during the periods were $988,385 and $2,696,776, respectively. When compared to the company posting minimal revenues for the comparable periods in FY 2013, we think it's an important milestone to recognize that revenues are continuing to build for the year. Also, during the nine months ending May 31, 2014, the company repaid over $700,000 of debt. It's evident from these results that we are executing our two-prong strategy that focuses on strategic acquisitions and debt reduction both of which have significantly enhanced Oncologix's market value.
2014 Key Company Activities through May 2014:
- Revenues for the three and nine months were $988,385 and $2,696,776, respectively.
- Rent Reductions: Reduced annualized rents by $50,000
- Acquired Amian Health Services - $1.1million in annual revenues
- Reduction in non-essential FTE employees- Realize annual savings over $75,000
- Began new product development for Dotolo Research Corporation Toxygen-II hardware system and new disposable products with E& R Engineering, Schmitt Engineering, and Atom Design
- Relocated Dotolo Research Corporation manufacturing facilities to E&R engineering manufacturing in Tempe, AZ
- Executed a $4.0 million line of credit facility with TCA Global Fund
- Increased our authorized shares to 750 million shares
- Repaid over $700,000 in debt during the nine months ending February 28, 2014
Erwin also noted, "To continue with current-year success, we'll execute further upon our acquisition strategy. We are currently in the final due diligence stage with three (3) additional companies, a medical device company with revenues exceeding $1,400,000 generating $600,000 in annualized earnings, and two medical product/equipment companies with combined revenues exceeding $18,000,000 and generating $2,100,000 in annualized earnings. Overall, our YE 2014 company objective is to reach $20,000,000 in annualized revenues by calendar end. We believe that our stock price is severely undervalued and by continuing on our debt reduction efforts and executing on strategic acquisitions, we will certainly expect an increase in our stock values in the near term."
Gegenüber dem letzten Quartal hat sich verändert, dass sie jetzt in der Endphase der Prüfung von drei (vorher: 2) Firmen sind und die bei einer Übernahme zu erwartenden Erlöse bei 20 (!) Millionen Dollar liegen sollen (vor drei Monaten: 10 Millionen Dollar).
Sieht doch mal richtig gut aus.
Das habe ich vorher in der Intensität noch nicht gesehen.
Das wird der Aktie in den kommenden Tagen und Wochen sicherlich helfen - Bekanntheit ist ja oft ganz entscheidend für den Erfolg einer Aktie - und OCLG hat hier eine Menge Potential zu bieten.
Oncologix Enters Medical Product & Technology Markets
ALEXANDRIA, LA / ACCESSWIRE / July 17, 2014 / Oncologix Tech Inc. (OTCPINK: OCLG), A diversified medical holding company with divisions in medical devices and healthcare services announces its expansion into the Medical Products and Technology markets.
Oncologix Tech, Inc (OCLG) recently formed a new division in its medical holding portfolio, Advanced Medical Products & Technologies, Inc. as a precursor into the medical product markets. The new division establishes a foundation for growth with future acquisitions of medical products, advanced technologies, product licensing and distribution. OCLG will position this business unit to service the growing aging demographic with advanced technologies designed to enhance medical service outcomes.
"Establishing our new Medical Products Division creates a solid base for expansion into this market segment," said CEO Wayne Erwin. "With an aging baby-boomer population, this industry will have significant growth opportunities and our objective is to utilize the new division as an operating platform to market, license and sell medical products via a national and international distribution network. By operational synergies and procurement economies, we can reduce the overall cost of products to patients, to health care service providers and be ideally positioned to meet the growing needs of a rapidly aging population".
"Our goal is to create a national and international sales distribution footprint," Erwin said. "We have identified several new technologies for product licensing and key acquisitions to be filtered through our distribution channels which will generate significant revenues with minimal capital investments."
About Oncologix Tech
Oncologix is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Healthcare Services, and provides sales and distribution of medical products and technologies. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services, and medical products and technologies. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company’s corporate mission is to be the best small cap medical device and healthcare services holding company in North America.
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Company's expectations, among other things, are dependent upon economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, its ability to operate its subsidiary companies effectively, need for and availability of more capital as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's filings with the Securities and Exchange Commission.
Contact Information
Wayne Erwin, Chairman and CEO
wayne.erwin@yahoo.com
(318) 451-9543
INVESTOR RELATIONS
Synergy: (888) 259- 9173
Irgendwie spannend zu beobachten, wie hier eine immer größer und erfolgreicher werdende Holding entsteht...und der Wert der Firma weiter lächerlich niedrig bleibt...
Gut, wer bei diesen Preisen zugreifen kann/will...und die Geduld mitbringt, die man hier sicher braucht, bis sich ein entsprechender Erfolg an der Börse einstellt.
http://www.ariva.de/oncologix_tech-aktie/times_and_sales?boerse_id=83 GrB
Optionen
| Boardmail an "buran" |
Wertpapier: Oncologix Tech Inc |
Mr. Halman brings 20+ years of new business development, medical sales, marketing and operations experience to OCLG. Prior to joining the company, Harold was the Chief Executive Officer for Global Medical located in Phoenix, Arizona, a national provider for home medical equipment. Mr Halman has vast knowledge and direct industry experience in medical devices and home medical products that will accelerate expansion within the company’s Medical Products and Technology Division both domestically and internationally. Prior to Global Medical, Mr. Halman was CEO of his management consulting firm involved in M&A, business turnarounds and business development projects. His direct experience includes bringing forth breakthrough medical products and technologies to the market with aggressive, multi-tiered distribution strategies.
"We are extremely pleased to have Harold join our management team" said Wayne Erwin, Chairman and CEO. "He has the industry experience we need in managing HME/DME providers, extensive manufacturer relationships, and we are confident that Harold will successfully drive new business growth for our new Medical Product Division".
Harold Halman resides in Phoenix, Arizona with his wife and two daughters.
About Oncologix Tech
Oncologix is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Healthcare Services, and provides sales and distribution of medical products and technologies. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services, and medical products and technologies. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company’s corporate mission is to be the best small cap medical device and healthcare services holding company in North America.
Forward-Looking Statements:
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Company's expectations, among other things, are dependent upon economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, its ability to operate its subsidiary companies effectively, need for and availability of more capital as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's filings with the Securities and Exchange Commission.
Contact:
Oncologix Tech Inc.
Wayne Erwin, Chairman and CEO
wayne.erwin@yahoo.com
(318) 451-9543
Investor Relations
Synergy:
(888) 259- 9173
SOURCE: Oncologix Tech Inc.
http://ih.advfn.com/p.php?pid=nmona&article=62990715
Jetzt sollten sie die Übernahmeverhandlungen abschließen und verkünden...und dann ist wohl endlich klarer, wohin die Reise bis Ende 2014 gehen kann/wird.
Was für ein Schnäppchen !
Oncologix (OCLG) Plans Expansion; Letter of Intent (LOI) Executed with Medical Product Company
ALEXANDRIA, LA / ACCESSWIRE / July 24, 2014 / Oncologix Tech Inc. (OCLG), a fully reporting, diversified medical holding company with operating businesses units in medical device, healthcare services and medical products and technologies, has executed a Letter of Intent (LOI) to acquire a speciality medical products company.
"This acquisition would be our first step in growing our Medical Products Division and would establish a national footprint of product distribution and brings numerous strategic advantages that will support our three primary distribution strategies including licensed Medicare businesses, wholesale/commercial distribution, and Government agencies" said Harold Halman, President/COO.
Mr. Halman added "our Division’s strategy is to create vertical approaches of market penetration to both the patients at home and the institutional healthcare industry with a full line of integrated solutions. Our continued acquisition/expansion strategy is to acquire company’s already positioned with strong product brands, market reach and identified with strong distribution centers located within large demographic, MSA areas."
Es scheint jetzt wiklich ernst zu werden mit der Umsetzung der angekündigten Strategie weiterer spektakulärer Zukäufe.
20 Millionen Erlöse in 2014 - da kommt noch richtig was GROSSES auf uns zu !
Macht Spaß, hier günstig zuzukaufen und zu warten, bis OCLG durch die Decke knallt.
http://www.ariva.de/oncologix_tech-aktie/times_and_sales?boerse_id=83 GrB
Optionen
| Boardmail an "buran" |
Wertpapier: Oncologix Tech Inc |